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Specific carbohydrates, i.e. prebiotics such as fructo-oligosaccharide (FOS), are not digested in the small intestine but fermented in the colon.
Besides beneficial health effects of an enhanced bifidobacteria population, intestinal gas production resulting from fermentation can induce
abdominal symptoms. Partial replacement with slowly fermented acacia gum may attenuate side effects. The aim was to compare the effects
of FOS with those of a prebiotic mixture (50% FOS and 50% acacia gum; BLEND) and a rapidly absorbed carbohydrate (maltodextrin) on general
intestinal wellbeing, abdominal comfort and anorectal sensory function. Twenty volunteers (eight male and twelve female; age 20–37 years) com-
pleted this double-blind, randomised study with two cycles of a 2-week run-in phase (10 g maltodextrin) followed by 5 weeks of 10 g FOS or
BLEND once daily, separated by a 4-week wash-out interval. Abdominal symptoms and general wellbeing were documented by telephone inter-
view or Internet twice weekly. Rectal sensations were assessed by a visual analogue scale during a rectal barostat test after FOS and BLEND
treatment. Both FOS and BLEND induced more side effects than maltodextrin. Belching was more pronounced under FOS compared with
BLEND (P¼0·09 for females; P¼0·01 for males), and for self-reported general wellbeing strong sex differences were reported (P¼0·002).
Urgency scores during rectal barostat were higher with FOS than BLEND (P¼0·01). Faced with a growing range of supplemented food products,
consumers may benefit from prebiotic mixtures which cause fewer abdominal side effects. Sex differences must be taken in consideration when
food supplements are used.
Prebiotics: Fructo-oligosaccharides: Acacia gum: Visceral perception: Gut comfort
Prebiotics have been defined as non-digestible food com-
pounds that selectively stimulate the intestinal flora and meta-
bolic activity after colonic fermentation. The human colon is
believed to be the predominant site of action and represents
the most heavily populated intestinal region with up to 1012
colony-forming units/ml(1). Lactobacilli and bifidobacteria
are considered indicator organisms of prebiotic stimulation;
in terms of gut health, bifidobacteria are currently considered
to be the most significant organisms(2). Dietary supplements of
a prebiotic such as fructo-oligosaccharides (FOS) increase the
content and proportion of bifidobacteria(2–5), which exert a
positive influence on gut health. Proliferation of these bacteria
allows a more predominant role for the intestinal flora as they
have been shown to decrease the quantity of potentially hazar-
dous bacteria by their metabolites and protect from intestinal
infections(6,7). Previous studies have documented positive
effects on absorption of nutrients and minerals(8), stimulation
of the immune system and synthesis of vitamins(9). Moreover,
prevention of constipation(10), colon cancer(11) and improve-
ment of blood sugar and lipid profile(12) are also attributed
to prebiotics.
Prebiotics are also employed as fat-replacers and to improve
food texture. For both health and technical reasons food products
are increasingly supplemented with prebiotics. In Europe, a
large range of prebiotic-supplemented food products is already
available. The most commonly used prebiotics in Europe are
FOS. The range of supplemented products includes (powdered)
milk and fermented milk products, cereals and clinical sup-
plements for pregnant women. FOS are naturally found in a var-
iety of vegetables such as asparagus, leeks, artichokes, onions
and garlic and have been classified as a food ingredient in the
European Union, Canada and Japan (‘generally recognised as
safe’ status in the USA) and are an acceptable food additive in
Australia andNewZealand(13). By-products of bacterial fermen-
tation of prebiotics are gases including H2, CO2, H2S and CH4,
which may cause intestinal discomfort, i.e. flatulence, bloating
and abdominal pain(14,15). Recently, the prebiotic properties of
acacia gum (Fibregumw (Colloı¨des Naturels International
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CNI, Rouen, France), a natural soluble fibre derived from acacia
gum) have been described and a synergy for the bifidogenicity
has been observed with the combination of FOS and acacia
gum(16). Due to the growing range of supplemented products,
consumers are exposed to increasing amounts of prebiotics
and may ingest daily doses above the threshold for induction
of side effects. In vitro fermentation time for acacia gum is
significantly longer than that for FOS and studies have suggested
a more favourable abdominal side-effect profile(17).
Replacement of a proportion of FOS by acacia gum may
thus attenuate the side effects of prebiotics with the additional
advantage of a synergistic effect on the growth of intestinal
bifidobacteria. Hence, the objectives of the present study
were primarily to compare changes in intestinal comfort and
secondarily to compare visceral sensitivity during rectal baro-
stat distension following long-term ingestion of a single pre-
biotic (FOS), a mixture of FOS and acacia gum (BLEND)
or a rapidly fermented carbohydrate (maltodextrin) in healthy
volunteers. In addition, independent of treatment phases,
determinants of wellbeing were analysed.
Methods
Subjects and study design
A total of eight male and twelve female healthy volunteers
completed this controlled, double-blind, cross-over, random-
ised trial. They were recruited from the University Hospital
and Universities in Zu¨rich by in-house advertisement. Candi-
dates with anal pathology, previous gastrointestinal surgery,
pregnancy, bowel dysfunction and drug abuse were excluded
from the study. Only candidates with normal findings and
ingesting a similar habitual diet, as assessed by a dietary ques-
tionnaire at the screening visit, were included in the study.
During a screening visit before acceptance for the study the
candidates underwent haematology, blood chemistry, urine
measurements, and a complete physical examination.
Women of childbearing potential were required to have a
negative urine pregnancy test. With the exception of birth con-
trol pills and hormone replacement therapy no regular medi-
cation was allowed during the study. Approval of the study
was granted by the Ethical Committee of the University Hos-
pital Zu¨rich (EK-926) and all participants gave their written
informed consent.
The study lasted a total of 18 weeks and was composed of
five testing periods:
(1) a first 2-week run-in period during which the volun-
teers ingested maltodextrin, and answered a diary and
a questionnaire;
(2) a 5-week ingestion period of the first product (FOS or
BLEND, diary, questionnaire);
(3) a 4-week wash-out period (no product intake, diary or
questionnaire);
(4) a second 2-week run-in period (maltodextrin, diary,
questionnaire);
(5) a 5-week ingestion period of the second product
(BLEND or FOS, diary, questionnaire).
The volunteers had to visit the study centre (visit 1, visit 2) at
the end of both 5-week treatment periods. The subjects came in
after a 6 h fasting period for stool specimen collection and baro-
stat testing of anorectal sensory function and rectal compliance.
Products
The products used were as follows:
(1) FOS: food-grade Raftilosew P95, produced by partial
hydrolysis of chicory root inulin, containing oligofruc-
tose, fructose, glucose and sucrose (ORAFTI, Tienen,
Belgium).
(2) BLEND: 1:1 mixture of FOS and acacia gum, a food-
grade purified alimentary fibre derived from acacia gum
(Fibregumw) consisting of branched arabino-galactans
polymers, as described previously(17).
(3) Maltodextrin, an easily digested, neutral, slightly sweet-
tasting carbohydrate obtained by hydrolysis of natural
maize starch (Glucidex; Roquette, Lestrem, France).
The starches are cooked and than acid and/or enzyme
treated to break them down into smaller polymers.
Doses and packaging
The subjects were asked to ingest daily, except for the
wash-out period, one sachet containing 10 g product 2 h
postprandially in a drink, for example, tea, coffee, mineral
water, soft drink or fruit juice. All products were packed
by Nestle´ (Konolfingen, Switzerland). Volunteers, support
stuff and investigators were blinded regarding the ingested
product. The run-in periods were not blinded since malto-
dextrin is sweet and easily recognised as compared with
FOS or BLEND.
The subjects received the first set containing the products,
questionnaires and diary for the first two periods at the screening
visit (visit 0) and the second set for the last two periods at visit 1.
Questionnaire
During the run-in and product intake periods, the volun-
teers answered twice weekly to a questionnaire by cellular
phone or Internet. The volunteers were contacted by an auto-
mated telemedical patient data-capturing system (Medcontrol
AG, 6314 Untera¨geri, Switzerland). The volunteers entered
information on gastrointestinal complaints and symptoms
of general wellbeing into the data-capturing system. The
questionnaire inquired about the occurrence and intensity
(none (0), slight (1), moderate (2), strong (3)) of:
(1) pain at stomach or abdomen during last 3 d (‘pain’);
(2) feeling bloated during last 3 d (‘bloat’);
(3) being disturbed by passing wind (‘wind’);
(4) being disturbed by belching or burping (‘belch’);
(5) being disturbed by frequent bowel movements during
last 3 d (‘DiaFreq’);
(6) being disturbed by urgent need to defecate (‘DiaUrg’);
(7) being disturbed by constipation (‘Obstip’);
(8) being bothered by frequent rumbling noise from stomach
or gut (‘borborygmi’);
(9) being adversely affected by nausea (‘nausea’);
(10) having suffered from heart burn or acid reflux (‘reflux’);
(11) being negatively influenced by ingestion of the products
(‘general’);
O. Goetze et al.1078
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(12) being forced to reduce daily activity, i.e. job, university,
household (‘work’).
In the figures, the sequence of the questionnaire items is
reordered by the frequency of reported symptoms, with
‘wind’ as most frequent first, and ‘reflux’ as least frequent
last. For quality control, a daily written diary for correspon-
ding evaluation of bloating, pain and nausea on a four-point
grading scale (none, slight, moderate, strong) and additional
evaluation of stool consistency (hard, normal, unformed,
watery), frequency of defecations as well as the time of pro-
duct intake was filled in by the volunteers. Since correspon-
ding questionnaire and diary outcomes correlated well in
preliminary analyses only the questionnaire data are reported.
Rectal barostat
The barostat procedure was performed in a left lateral 158
Trendelenburg position (the body is laid flat on the back
(supine position) with the feet higher than the head).
A 10 cm-long polyethylene balloon was inserted into the
rectum such that the proximal end was 5 cm inside the anal
verge. Minimal distending pressure was determined by
1mmHg/min stepwise rectal expansion until changes in respir-
atory excursion were apparent (at about 30ml balloon
volume). Then a conditioning distension was performed,
inflating the balloon by 2mmHg increments every 30 s in
the range of 0–40mmHg to avoid changes in compliance
and sensation in subsequent inflations.
Rectal compliance was assessed twice by 2mmHg stepwise
increments of intra-balloon pressure beginning at 0mmHg
pressure up to 40mmHg or until subjects reported pain.
During the last 10 s of each pressure increase, the volunteers
were asked to score their perception of lower abdominal sen-
sation using a six-point graphic-rating scale ranging from
‘no feeling’ to ‘painful’. After a 15min break, phasic rectal
distensions at 12, 24, 36 and 42mmHg pressure above mini-
mal distending pressure were performed in randomised
order. During the last 15 s of each random distension, subjects
were asked to rate their abdominal symptoms, i.e. the urgency
to defecate (‘urgency’), bloating (‘wind’), discomfort (‘dis-
comfort’) and pain (‘pain’) using a 100mm visual analogue
scale (VAS) with ‘none’ at 0 and ‘worst ever’ at 100. The
equilibration interval between distensions was 2min at mini-
mal distending pressure. The method of measuring anorectal
sensation and compliance was described in detail in previous
studies of our laboratory(18,19).
Stool microflora
Freshly passed faecal samples were placed into cryotubes and
frozen in liquid N2 and kept at 2708C until analysis at the
Nestle´ Research Centre using fluorescent in situ hybridis-
ation. The probe used in the study was Bif164, specific for
Bifidobacterium (5).
Data analysis and statistics
The comparison of the questionnaire between FOS and
BLEND was the primary outcome of the present study. Sec-
ondary outcomes were:
(1) comparison of questionnaire scores between treatment
phase (FOS or BLEND) and run-in;
(2) intra-subject correlation of intestinal symptoms with
general and work wellbeing to identify the dominant
physiological correlate of intestinal comfort;
(3) comparison of visceral sensitivity under FOS and
BLEND, as measured by VAS scores during rectal dis-
tension;
(4) composition of the faecal microflora under FOS and
BLEND.
For the primary endpoint, questionnaire outcomes were
dichotomised into 0 and 1, where 0 means ‘no symptoms
reported’. The binary data were analysed with a generalised
linear mixed model (GLMM), logistic link, and quasi-binomial
family. Subject was the random term, sex and treatment (FOS or
BLEND) and their interaction term were fixed terms; the sub-
ject’s run-in means pooled over both phases were used as a cov-
ariable. The GLMM model is considered robust against
unbalanced sex distributions. Results were reported as odds
and OR with CI. All CI and P values for the questionnaire ana-
lysis were computed as contrasts of the GLMM analysis. No
adjustments for multiple testing were applied to P values and
CI. For questionnaire item 10 (‘reflux’), which was reported
by four subjects in only twenty out of 582 calls, the GLMM
procedure did not converge, and therefore was removed from
primary endpoint analysis. For questionnaire item 12 (‘work’),
the fitted probability for the male subgroup is close to zero,
which can result in a high false-alarm rate; this item was also
analysed by the Markov-Chain Monte-Carlo (MCMC) GLMM
procedure to check for robustness.
Symptoms in the run-in phase were not significantly differ-
ent from each other, and were pooled per subject. For com-
parison against the run-in phase as secondary outcome, a
GLMM analysis was done without sex breakdown to avoid
convergence problems when sex was used as a factor.
The influence of intestinal symptoms on general wellbeing
(‘general’) and on being forced to reduce daily activity
(‘work’) were analysed by multiple regression analysis and
best predictors were reported as adjusted squared correlation
coefficients.
Rectal functional parameters and threshold pressures as
assessed by rectal barostat were analysed by exact Wilcoxon
matched pair tests. VAS scores were transformed by an
offset logarithmic transformation (log (VAS þ5)) in order
to stabilise variances and expressed as CI of VAS-equivalent
balloon stimulation pressures. The slopes of VAS and graphic
ratings, computed with pressure as the independent variable,
served as a measure of rectal sensitivity. Slopes were deter-
mined separately for each sensation (wind, urgency, pain, dis-
comfort), and for the sensation sum score by a linear mixed
model, with subject as a random variable and treatment as
fixed. For analysis of continuous data, a linear mixed model
was used, using power weighting if required based on inspec-
tion of residual distribution. The logarithms of the total stool
bacteria count and the bifidobacteria count were analysed by
paired t tests.
Data were considered significant at a level of a #0·05. All
statistics were evaluated and plotted using the open-source
computing environment ‘R’ (version 1.9.0; R Foundation for
Statistical Computing, Vienna, Austria). Mixed models were
Prebiotics and intestinal wellbeing 1079
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estimated with package nlme under R(20) and function
glmmPQL in MASS(21); the MCMC model was computed
with DPpackage(22).
Results
Eight male and twelve female healthy volunteers (median age
28 (range 20–37) years) of normal BMI (median 22·5 (range
20·1–25·3) kg/m2) and weight (median 67 (range 53–84) kg)
completed the study without any complications or adverse
events. Valid questionnaire responses were obtained in 154
of 160 possible responses of the run-in phase (96%) and in
426 of 440 possible responses (97%) of the treatment
phases, indicating very high compliance rates.
Fructo-oligosaccharide v. prebiotic mixture of fructo-
oligosaccharide and acacia gum
The most frequently reported symptoms for both FOS and
BLEND were ‘bloating’ and ‘wind’, with an odds over 1, cor-
responding to more than 50% of the calls (Fig. 1). The most
prominent difference between FOS and BLEND was found for
item 11 (‘general wellbeing’) of the male group, which was
larger under FOS treatment (Fig. 2 (a)) with an OR of 9·6
(P¼0·002). To check whether this was a statistical artifact
of the GLMM method(23), a Bayesian estimate(22) was com-
puted for this item giving an even larger OR for the sex differ-
ence of 27 (95% CI 4·3, 121; P values commonly not given
for Bayesian methods).
The higher incidence of ‘belching’ under FOS (P¼0·09 for
females; P¼0·01 for males) had the same tendency for both
sexes. ‘Bloating’ under FOS and BLEND was expressed dif-
ferently for sex, as computed from the interaction term in
the GLMM (Fig. 2 (b), and last column in Table 1;
P¼0·008) with an OR of 1·3 ( ¼ higher under FOS) for
females and 0·3 ( ¼ lower under FOS) for males. Most symp-
tom scores increased during the treatment intervals and the
run-in period (Fig. 3).
Fructo-oligosaccharide and prebiotic mixture of fructo-
oligosaccharide and acacia gum v. run-in
The response scores for ‘bloating’ and ‘wind’ were signifi-
cantly higher during FOS and BLEND treatment as compared
with the pooled run-in period (P,10210 for both items and
sexes). Occurrence of ‘borborygmi’ was significantly
increased in both phases (P,1025). ‘General’ wellbeing
under FOS was reduced compared with run-in (OR 5·4;
P,1027), but less under BLEND (OR 2·9; P¼0·001), an
effect that was overlaid by the extreme sex differences for
this item. ‘Nausea’ and ‘reflux’ were almost never reported.
Fig. 1. Odds of reported ‘symptoms present’ to ‘symptoms absent’ for once-
daily ingestion for 5 weeks of a 10 g prebiotic mixture of food-grade fructo-
oligosaccharide (FOS; Raftilosew P95) and acacia gum (1:1; BLEND) (a) and
for once-daily ingestion for 5 weeks of 10 g FOS (b). Horizontal bars rep-
resent 95 % CI from generalised linear mixed model analysis of questionnaire
data. CI are between-subjects and it is not valid to visualise within-subject
tests against run-in. Odds are on a logarithmic scale; the dotted vertical line
shows the value of 50 % reported calls with non-zero symptoms. Items are
ordered by overall frequency of reporting. (K), Females, baseline values; (O),
females, treatment values; (W), males, baseline values; (X), males, treatment
values; Obstip, being disturbed by constipation; Borbor, borborygmi; DiaUrg,
being disturbed by urgent need to defecate; DiaFreq, being disturbed by
frequent bowel movements during last 3 d. For further details of the question-
naire items of the automated telemedical data-capturing system, see
Methods.
Fig. 2. (a) Symptom score OR on a logarithmic scale of once-daily ingestion
for 5 weeks of 10 g food-grade fructo-oligosaccharide (FOS; Raftilosew P95)
v. once-daily ingestion for 5 weeks of a 10 g prebiotic mixture of food-grade
FOS and acacia gum (1:1; BLEND) for females (O) and males (X), with 95 %
CI represented by horizontal bars. (b) Between-sexes FOS v. BLEND diffe-
rence from interaction term in generalised linear mixed model. The dotted
vertical line at the OR of 1 corresponds to ‘no difference in reported
frequency’. m, Males; f, females; Obstip, being disturbed by constipation;
Borbor, borborygmi; DiaUrg, being disturbed by urgent need to defecate;
DiaFreq, being disturbed by frequent bowel movements during last 3 d.
For further details of the questionnaire items of the automated telemedical
data-capturing system, see Methods.
O. Goetze et al.1080
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During run-in only 14% of all responses to the questionnaire
were larger than 0 indicating slight (in most of the cases),
moderate, or strong effects. Of the responses under FOS and
BLEND, 30% were larger than 0.
Determinants of gut comfort
Irrespective of the treatments, in both sexes changes in
gut symptoms affected ‘general’ wellbeing more strongly
(R 2 .0·35) than wellbeing during ‘work’ (R 2 .0·20;
Fig. 4). In men, ‘borborygmi’ were the strongest determinant
of gut comfort (R 2 .0·26). Stool-related symptoms were
secondary for males. In priority sequence, ‘bloating’, ‘wind’
and ‘stool frequency’ were main determinants of wellbeing
in women. ‘Belching’, which was significantly higher under
FOS, is a major determinant for general wellbeing, but is
not a relevant factor influencing work.
Rectal barostat
No significant effects of treatment type on rectal compliance
and asymptotic compliance were detected. Threshold press-
ures and rectal sensations (urgency, wind, discomfort and
pain) were also similar for all treatments during phasic disten-
sion (Table 2). In the GLMM analysis of dichotomised sen-
sory responses the scores for urgency were higher under
FOS compared with BLEND (OR 2·2; P¼0·01), with discom-
fort and pain showing the same tendency (Fig. 5).
Stool analysis
No differences in faecal bifidobacteria concentration and
the number of total bacteria as well as bifidobacteria:total
bacteria ratio were observed between FOS and BLEND
(bifidobacteria: 9·8 (SD 0·3) v. 9·7 (SD 0·4) log colony-for-
ming units/g; total bacteria: 10·4 (SD 0·3) v. 10·4 (SD 0·3)
log colony-forming units/g).
Discussion
The main results of the present study were: (i) evidence to
suggest that FOS generates slightly more abdominal side
effects than acacia gum; (ii) indication of sex differences of
determinants in gut wellbeing; (iii) confirmation that self-
observation induces a sensitisation or higher level of alertness
to gut signals; (iv) that patient monitoring using an automated
telemedical data-capturing system assures excellent question-
naire response rates.
The differences between scores for FOS and BLEND were
small, i.e. smaller than those between both product periods
and the run-in period; only belching was significantly stronger
under FOS in both sexes. It remains to be elucidated whether
the daily 10 g supplement was simply below the threshold for
the induction of more pronounced effects, and to what extent
sexes differ in their response to fibre supplementation.
Sex differences in transit time, faecal weight and biochem-
istry and in dietary fibre intake have been reported(24) and
either of these differences may explain the weaker sex-specific
responses. The results of the present study support the occur-
rence of sex differences in response to prebiotic supplemen-
tation as has been observed in studies describing sex
differences in response to dietary fibre supplements(25–27).
These effects surpass a purely symptomatic response: com-
bined data from two large intervention trials(28) revealed that
dietary fibre both as a supplement or in a high-fibre diets pro-
tect men but not women against colorectal adenoma recur-
rence(26,28). Sex differences in brain responses to rectal
distention have also been reported, suggesting different
neural processing or behavioural changes to the perception
of gut stimuli(29–31). Not surprisingly, in the present study
sexes differed also in their perception of behavioural changes
induced by ingestion of dietary prebiotics. These sex differ-
ences need to be taken in account when targeting populations
of both sexes with dietary fibre supplements, as has already
been done for recommended daily fibre intake. Further exper-
iments are needed to confirm and characterise the sex differ-
ences in response to fibre ingestion. The inclusion of larger
doses of fibre supplements would certainly answer the ques-
tions about threshold doses in both sexes, and could also con-
firm sex differences.
Both products significantly enhanced scores for bloating
and wind. ‘Borborygmi’ were significantly enhanced under
treatment with FOS. Moreover, there was a tendency for
enhanced scores for belching and ‘general’ impairment
under FOS only. Only 30% of all responses to the question-
naire during FOS or BLEND were larger than zero, suggesting
that the supplemented dose had generally small effects on
abdominal symptoms. Nonetheless, both FOS and BLEND
showed significant effects as compared with the run-in phase
with maltodextrin. It remains unclear whether carrying out
the run-in period in an unblinded way may have contributed
to the size of the effects between FOS or BLEND and run-
in. The increase in some of the symptoms during the treatment
periods was rather surprising. In fact, adaptation to the 10 g
supplement was to be expected; however, symptoms generally
tended to increase over time (Fig. 3). The increase was also
observed during the run-in (maltodextrin) periods, suggesting
that it is rather a higher level of alertness in self-observance
that leads to the ‘sensitisation’ than the product itself.
Table 1. Fructo-oligosaccharide (FOS) v. prebiotic mixture of FOS and
acacia gum for primary endpoint questionnaire items, by sex*
(Odds ratios)
Females Males
Males–
females
Item OR† P OR† P OR† P
Wind 0·9 0·7 2·6 0·03 3·0 0·06
Bloat 1·3 0·4 0·3 0·008 0·2 0·008
DiaFreq 0·6 0·2 1·2 0·7 1·8 0·2
DiaUrg 0·9 0·8 0·7 0·5 0·8 0·6
Borborygmi 1·8 0·1 0·7 0·4 0·4 0·08
General 1·1 0·6 10·9 3£1024 9·6 0·002
Pain 0·7 0·3 0·4 0·05 0·6 0·4
Work 1·8 0·06 0·3 0·1 0·2 0·03
Belch 3·2 0·09 3·7 0·01 1·2 0·9
Obstip 0·7 0·3 0·4 0·1 0·6 0·4
Nausea 0·5 0·2 0·2 0·01 0·4 0·2
* For abbreviations of the questionnaire items of the automated telemedical data-
capturing system, see Methods.
† OR .1 indicate more frequent symptoms under FOS. The P values test against
the null hypothesis of an OR ¼1·0; no correction for multiple testing has been
applied.
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The sensory score for ‘urgency’ during the barostat test was
significantly higher under FOS than under BLEND, with ‘dis-
comfort’ and ‘pain’ having the same tendency. The differences
between FOS and BLEND point in the same direction as the
questionnaire results. An increase in urgency in the question-
naire, with no additional stimulus applied, was not observed
under FOS.
To evaluate further differences between FOS and
BLEND, concentrations of bifidobacteria as indicators of
gut health were quantified. There were no significant differ-
ences in gut bifidobacteria concentration or total bacterial
content between FOS and BLEND, probably due to the
low dose of prebiotic supplemented in the present study.
Possibly, the replacement of a large proportion of the
fibres ingested with the regular diet by FOS or BLEND
would have helped to reveal differences between the sup-
plements as well as between the run-in periods and the sup-
plements. This had not been addressed in the present study
to avoid increasing the cumbersome stool collections to a
total of four collections.
In general, prebiotics are safe and mainly well-tolerated
food supplements with only slight differences as observed
between the products FOS and BLEND. However, BLEND
did show a slightly more favourable side-effect profile in com-
parison with FOS, supporting the concept of slower fermenta-
tion in the genesis of abdominal symptoms. Further
Fig. 3. Smoothed time series of symptom scores by treatment. (—), Pooled score results of the two 2-week baseline phases with 10 g maltodextrin once daily
(run-in); (. . .), score results of the 5-week ingestion period of 10 g food-grade fructo-oligosaccharide (FOS; Raftilosew P95) once daily; (–-), score results of the
5-week ingestion period of a 10 g mixture (1:1) of FOS and acacia gum once daily (BLEND). The symptoms are (a) wind, (b) bloating, (c) being disturbed
by frequent bowel movements during last 3 d, (d) being disturbed by urgent need to defecate, (e) borborygmi, (f) general wellbeing, (g) pain, (h) reducing daily
activity (work), (i) belching, (j) being disturbed by constipation, (k) nausea, (l) reflux. For further details of the questionnaire items of the automated telemedical
data-capturing system, see Methods.
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Fig. 4. Main determinants of intestinal symptoms for items ‘General’ (reduced general wellbeing) (a and b) and ‘Work’ (influence at work) (c and d) for males
(a and c) and females (b and d). Initially all ten other questionnaire item scores were used to predict ‘General’ and ‘Work’ score respectively, and an Akaike infor-
mation criterion-controlled subsets regression reduced predictors to the four most dominant ones. The vertical scale shows adjusted squared correlation coeffi-
cient; for example, for n 5/13 %, five of the eight male subjects included in the study reported non-zero symptom score values, and overall 13 % of the responses
were .0. borbor, Borborygmi; obstip, being disturbed by constipation; DiaFreq, being disturbed by frequent bowel movements during last 3 d; DiaUrg, being dis-
turbed by urgent need to defecate. For further details of the questionnaire items of the automated telemedical data-capturing system, see Methods.
Table 2. Rectal function and sensations after a 5-week period of fructo-oligosaccharide
(FOS) or prebiotic mixture of FOS and acacia gum (BLEND) ingestion as assessed
by barostat*
(Medians and interquartile ranges (IQR) for twenty subjects)
FOS† BLEND‡
Rectal barostat Median IQR Median IQR
Rectal pressure (mmHg) 3·7 1·9–4·0 3·4 2·7–4·8
Rectal compliance (ml/mmHg) 16·1 12·6–20·8 15·7 13·7–25·8
Asymptotic compliance (ml/mmHg) 4·93 4·01–6·35 5·43 4·97–6·43
Threshold pressures
Vague (mmHg) 6·35 3·98–8·35 7·29 5·66–9·88
Pain (mmHg) 35·9 26·1–41·9 39·9 25·7–42·9
Rectal sensation at 36 mmHg
VAS urgency (mm) 74 47–92 62 46–84
VAS wind (mm) 14 0–53 31 5–47
VAS discomfort (mm) 83 48–93 66 48–97
VAS pain (mm) 55 19–76 38 10–78
VAS, visual analogue scale.
* No significant differences in sensory scores were found using a mixed model analysis, and there
were no differences in rectal functional parameters and threshold pressures by exact Wilcoxon matched
pair tests.
† Functional parameters after a 5-week ingestion period of 10 g food-grade Raftilosew P95 once daily.
‡ Functional parameters after a 5-week ingestion period of a 10 g mixture (1:1) of FOS and acacia gum
once daily.
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experiments are needed to confirm and characterise the sex
differences in response to fibre ingestion. The inclusion of
larger doses of fibre supplements would clarify the role of
sex-specific threshold doses.
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